摩洛哥大学医院药物警戒现状评估
该研究于2023年评估摩洛哥7个大学医院中心(含30家医院)的药物警戒活动实施情况,使用结构化问卷和WHO指标对28项活动评分。结果显示47%医院已建立药物警戒活动,30%部分实施,23%未实施或仅有基础活动。工作组据此提出建议并于2023年7月正式制度化。
要点
- 47%医院已建立药物警戒活动,含信号检测与因果关系评价
- 30%医院部分实施,23%未实施或仅有基础活动
- 疫苗警戒在多数医院被降级处理
核心结论
- 评估发现部分中心已具备良好的不良事件信号检测和因果关系评价能力,可在全国发挥引领作用。
- 通过协作方式汇集联络人确定下一步并形成共识,有助于推动各中心药物警戒正式化。
研究设计与样本
- 2023年对摩洛哥7个大学医院中心(含30家医院)进行结构化问卷调查,问卷基于WHO药物警戒指标和全球基准工具开发。
- 数据归为28项药物警戒活动,每项评分0(未实施)至3(完全实施),并计算各站点实施率。
- 同时进行现场文件审查,并由三个利益相关方工作组基于评估结果制定建议。
主要发现
- 所有被评估的大学医院中心均具备药物警戒基本要素(通知表和VigiFlow®或Excel数据库)。
- 14家医院(47%)药物警戒活动已良好建立,包括药品和疫苗使用后不良事件信号检测及因果关系评价等高级活动。
- 9家医院(30%)部分实施药物警戒,7家医院(23%)未建立活动或仅有非常基础的活动。
- 在4个大学医院中心内,各医院间活动实施水平不一致,疫苗警戒在很大程度上被降级处理。
关键数值与推荐
- 实施率分级标准:完全实施的活动占比≥70%为良好建立,>40%且<70%为部分实施,≤40%为未实施。
临床怎么用
- 临床药学智能体可参考本评估框架识别药物警戒薄弱环节,优先强化信号检测与因果关系评价能力。
- 针对疫苗警戒被降级的情况,应推动各中心均衡开展药品与疫苗不良事件监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Despite the increased scrutiny on vaccine safety following the coronavirus disease 2019 (COVID-19) pandemic, Morocco's Centre of Antipoison and Pharmacovigilance (CAPM) remained concerned that the pharmacovigilance system in Morocco was insufficiently implemented, including limited adverse event (AE) reporting, poor data use, and inconsistent training nationwide. OBJECTIVES: We sought to assess the status of pharmacovigilance activities (PAs) prior to formally institutionalizing them across university hospital centers (UHCs), given their position as the main providers of healthcare in Morocco and key sources for reporting serious AEs. METHODS: We assessed seven UHCs (housing 30 hospitals) in 2023 using a structured questionnaire with pharmacovigilance focal points developed from the World Health Organization's indicators of pharmacovigilance and the Global Benchmarking Tool. Data were grouped into 28 PAs and scored from 0 (not implemented) to 3 (fully implemented). We then calculated an implementation rate for each site on the basis of percent of PAs fully implemented (≥ 70%, well established; > 40% to < 70%, partially implemented; and ≤ 40%, not implemented). A desk review was also performed at the sites. Using the results of the assessment, three working groups of pharmacovigilance stakeholders developed recommendations to be formally adopted by UHCs. RESULTS: Basic elements of pharmacovigilance (notification forms and VigiFlow® or Excel databases) were present at all the UHCs assessed. In total, 14 hospitals (47%) had well-established PAs, including advanced activities such as signal detection of adverse events following the use of medicines and vaccines, as well as causality assessment; 9 hospitals (30%) were partially implementing pharmacovigilance, and 7 hospitals (23%) had no established activities or very basic activities. Within four UHCs, activities had not been implemented at the same level from one hospital to another and vaccine vigilance was largely deprioritized. The working groups made recommendations for improving collaboration, standardizing procedures, and outlining a new organizational structure for pharmacovigilance, which was institutionalized by a formal agreement among UHCs in July 2023. CONCLUSIONS: The assessment revealed a subgroup of centers with well-established AE signal detection and causality assessment abilities, which could play a leading role in the country. After the site assessment, our collaborative approach of bringing together focal points to identify next steps and generate buy-in helped to formalize pharmacovigilance across centers.
引用
- Hamzaoui H, Shaum A, Cherkaoui I, et al. Assessment of Pharmacovigilance Across University Hospitals in Morocco. Drug Saf. 2025. PMID: 39939518. doi:10.1007/s40264-025-01517-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。